The FDA advisory panel meeting was held to address proposed changes to the iPLEDGE REMS to minimize burden on patients, prescribers, and pharmacies while maintaining safe use of isotretinoin.
The 19-day lockout, home pregnancy tests, and attestation intervals for counseling people who cannot get pregnant were among the hot topics on the first day of a 2-day meeting.